Marinus Pharmaceuticals Inc (NASDAQ:MRNS) currently has a daily average trading volume of 2.15M but it saw 738548 shares traded in last market. With a market cap of 84.59M USD, the company’s current market price of $1.54 came rising about 6.94 while comparing to the previous closing price of $1.44. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.26 and as low as $1.11.
Taking a look at 20-day trading activity of Marinus Pharmaceuticals Inc (MRNS) gives us an average price of $1.3913, while its current price level is -86.32% below from 52-week high level whereas it is 38.74% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $3.2367 while that of 200 days or SMA-200 reads an average of $7.0333. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.58% during that period while stretching the period over a month that decreases to 9.22%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.05 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Robert W. Baird which downgraded the stock as “Neutral” in its note to investors issued on April 16, 2024, recommending a price target of between $20 and $2 for it. RBC Capital Mkts downgraded its recommendation for the stock as a “Sector Perform” from “Outperform” on April 15, 2024 while assigning a price target range of $24-$3. Oppenheimer also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $14 and $9.
Year-to-date it is -85.83% down and over the past year, the stock is showing a downside performance of -79.38%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.61 beat the consensus estimate of -0.72 for the same. In next quarter, company is expected to be making quarterly sales of $10.23M as analysts are expecting the sales for current fiscal year at $39.34M and seeing the company making $58.17M in sales next year. Moreover, analysts are in estimates of $9.49M for current-quarter revenue.
Currently, Marinus Pharmaceuticals Inc’s total number of outstanding shares is 54.58M. Company’s return on investment (ROI) stands at -189.10% and return on equity (ROE) at -423.43%. Stock’s beta reads 1.15. Stock has a price to sale or P/S ratio amounts to 2.99. Its return on asset (ROA) is -79.82% on average.
